Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of Oraxol in cancer patients
2017-004578-33Phase 2Unknown
- Sponsor
- Athenex
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel + encequidar in cancer (2 arms), sponsored by Athenex. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 2 more. Status: unknown.
02
Drugs
paclitaxel + encequidar
03
Conditions
cancer
Beyond the preview
Go deeper on 2017-004578-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004578-33.